ストックスクリーナーアプリを入手
843.63
0.17%
-1.42
プレマーケット:
847.18
3.55
+0.42%
Lilly Eli Co (LLY) 最新ニュース
Puzo Michael J Has $3.57 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
Kidder Stephen W Grows Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Somerville Kurt F Has $5.65 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly Stock Eases After-Hours: Ex-FDA Official Ejected By RFK Jr. Joins Firm — Will Investors Warm Up? - MSN
Major Shareholder Makes a Massive Move with Eli Lilly & Co Stock! - TipRanks
Analysis: Cork operations of Eli Lilly underpin Ozempic maker Novo Nordisk's dwindling market dominance - Irish Examiner
Peter Marks finds a new home at Eli Lilly - FirstWord Pharma
Eli Lilly taps former US FDA official Peter Marks to head infectious disease - Yahoo
Peter Marks, FDA vaccine regulator ousted by RFK Jr., joins Eli Lilly - statnews.com
Former FDA CBER Head Peter Marks Joins Eli Lilly Six Months After Departure - geneonline.com
Former FDA vaccine regulator takes job at Eli Lilly - Washington Examiner
Marks Finds His Next Role as Lilly Snags Another Former FDA Regulator - BioSpace
Peter Marks, former top FDA vaccine official, joins Eli Lilly - BioPharma Dive
Lilly Endowment sells $137 million in Eli Lilly shares - Investing.com
Eli Lilly (LLY) Stock Rises Amid New Executive Appointment - GuruFocus
Former FDA vaccine regulator Peter Marks joins Eli Lilly - StreetInsider
Eli Lilly says Peter Marks named senior VP of molecule discovery & head, infectious disease - MarketScreener
After high-profile FDA exit, Peter Marks lands at Eli Lilly - Fierce Biotech
Former FDA Official Joins Eli Lilly (LLY) for Research Leadershi - GuruFocus
Former FDA vaccine chief Peter Marks joins Eli Lilly - Yahoo
Eli Lilly (LLY) Strengthens Leadership with New Infectious Disea - GuruFocus
Lilly Hires Ex-FDA Official as Infectious Disease Head - Bloomberg.com
How Eli Lilly And Company (LLY) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Former FDA CBER Director Peter Marks lands at Eli Lillyreport - Seeking Alpha
Wegovy, Ozempic Maker Novo Nordisk Cuts Staff At Key US Production Sites - Benzinga
Lilly’s Omvoh benefit continues for four years in UC - Clinical Trials Arena
Eli Lilly (LLY) Reports Promising Long-Term Results for Omvoh in Ulcerative Colitis - GuruFocus
Lilly to spend more than $1B to expand operations in India - dailyjournal.net
Eli Lilly's Mounjaro logs ₹80 crore in September, India's No. 2 drug - Business Standard
Eli Lilly & Co (LLY) Receives a Buy from Bank of America Securities - The Globe and Mail
Eli Lilly to Invest Over $1 Billion in India | - Chemical Industry Digest
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know - Yahoo Finance
Eli Lilly earmarks $1B to boost India manufacturing footprint - Endpoints News
US pharmaceutical giant Eli Lilly & Co. will invest more than $1 billion in India to expand its contract manufacturing operations and introduce new therapies, including an oral version of its experimental weight-loss drug, orforglipron, ET reported. The investment - instagram.com
Eli Lilly to Invest $1 Billion in India to Boost Contract Manufacturing and Global Medicine Supply - KNN India
Company of the Year 2025: Eli Lilly – Among the heavyweights - PharmaLive
Eli Lilly (LLY) Unveils Promising Long-Term Results for Ulcerati - GuruFocus
Eli Lilly reports final results from LUCENT-3 study of Omvoh - TipRanks
Lilly’s Omvoh shows sustained 4-year efficacy in ulcerative colitis - Investing.com
Eli Lilly strikes AI drug discovery deal with US biotech - Life Sciences Intellectual Property Review
Lilly's Omvoh (mirikizumab-mrkz) is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis - Eli Lilly and Company
Eli Lilly’s $1 billion India investment to boost local CMOs and suppliers - Business Today
Eli Lilly to invest more than $1B in India, Reuters reports - The Globe and Mail
Eli Lilly’s Bets $1B India as U.S. Tech Investment Slows Under Tariff Pressure - Tekedia
Eli Lilly's $1 billion India plan to bring fresh jobs for engineers, pharma grads - India Today
Eli Lilly plans major $1bn expansion in Telangana, India - Investment Monitor
Eli Lilly to Invest ₹9,000 Crore in Hyderabad, Boost Telangana’s Pharma Leadership - Analytics India Magazine
Eli Lilly to invest over USD 1 billion in India - medwatch.com
Eli Lilly bets big on India with $1 billion manufacturing push - Healthcare Radius
Eli Lilly To Invest Over USD 1 Bn to Boost Manufacturing in India - Entrepreneur
Eli Lilly plans to invest over USD 1 billion in new contract manufacturing in India - Medical Dialogues
US pharma giant Eli Lilly to invest over $1 billion in Telangana - The News Minute
US pharma major to invest $1 billion in Telangana - The New Indian Express
Major Shareholder Sells Massive Stake in Eli Lilly & Co! - TipRanks
Eli Lilly to Invest $1 Billion in Telangana to Boost Global Pharma Supply - Newsonair
Eli Lilly to invest US$1 billion in India contract manufacturing - The Business Times
Eli Lilly to inject $1 billion in contract manufacturing operations in India - MSN
Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal - MSN
$1000 Invested In Eli Lilly 10 Years Ago Would Be Worth This Much Today - Benzinga
Eli Lilly to Invest Over $1 Billion in India to Expand Manufacturing Network - Yahoo
Eli Lilly, maker of weight loss drug Mounjaro, to contract manufacture in Telangana, promises $1 billion investment - The Indian Express
Lilly Endowment sells Eli Lilly & Co (LLY) shares worth $161 million - Investing.com
Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know - The Globe and Mail
Eli Lilly to invest $1 billion in India, expand manufacturing and introduce oral weight-loss drug - The Economic Times
US pharma major Eli Lilly to inject $1 billion in new Hyderabad hub - Times of India
Eli Lilly's $1 Billion India Gamble Signals Pharma's Next Global Power Shift - Yahoo Finance
Eli Lilly Plans To Spend $1B In India To Expand ManufacturingEli Lilly (NYSE:LLY) - Benzinga
0.39%
0.53%
大文字化:
|
ボリューム (24 時間):